143 related articles for article (PubMed ID: 27160228)
21. Paradoxical antitumor effects of pazopanib in a cutaneous angiosarcoma patient.
Hoashi T; Hirabayashi M; Nakajima R; Takahashi N; Saeki H
J Dermatol; 2017 Sep; 44(9):1078-1079. PubMed ID: 27726177
[No Abstract] [Full Text] [Related]
22. Pazopanib: a Review in Advanced Renal Cell Carcinoma.
Frampton JE
Target Oncol; 2017 Aug; 12(4):543-554. PubMed ID: 28664385
[TBL] [Abstract][Full Text] [Related]
23. Establishment of a novel experimental model of human angiosarcoma and a VEGF-targeting therapeutic experiment.
Hoshina D; Abe R; Yoshioka N; Saito N; Hata H; Fujita Y; Aoyagi S; Shimizu H
J Dermatol Sci; 2013 May; 70(2):116-22. PubMed ID: 23522954
[TBL] [Abstract][Full Text] [Related]
24. [Pharmacological profile and clinical results in advanced soft tissue sarcoma patients of pazopanib hydrochloride (Votrient(®))].
Arai H; Fukasawa N; Ueta F
Nihon Yakurigaku Zasshi; 2013 Jan; 141(1):37-42. PubMed ID: 23302947
[No Abstract] [Full Text] [Related]
25. Refractory metastasis of cutaneous angiosarcoma showing complete response to pazopanib.
Fujiwara S; Nagai H; Nakamachi Y; Kawano S; Nishigori C
Eur J Dermatol; 2015; 25(1):71-3. PubMed ID: 25679339
[No Abstract] [Full Text] [Related]
26. Effect of pazopanib on tumor microenvironment and liposome delivery.
Tailor TD; Hanna G; Yarmolenko PS; Dreher MR; Betof AS; Nixon AB; Spasojevic I; Dewhirst MW
Mol Cancer Ther; 2010 Jun; 9(6):1798-808. PubMed ID: 20515941
[TBL] [Abstract][Full Text] [Related]
27. Inhibitory activity of ranibizumab, sorafenib, and pazopanib on light-induced overexpression of platelet-derived growth factor and vascular endothelial growth factor A and the vascular endothelial growth factor A receptors 1 and 2 and neuropilin 1 and 2.
Kernt M; Thiele S; Neubauer AS; Koenig S; Hirneiss C; Haritoglou C; Ulbig MW; Kampik A
Retina; 2012 Sep; 32(8):1652-63. PubMed ID: 22466477
[TBL] [Abstract][Full Text] [Related]
28. Pazopanib in ovarian cancer.
McLachlan J; Banerjee S
Expert Rev Anticancer Ther; 2015; 15(9):995-1005. PubMed ID: 26296187
[TBL] [Abstract][Full Text] [Related]
29. Pazopanib-Associated Transient Ischemic Attack.
Revuelta-Herrero JL; Escudero-Vilaplana V; Álvarez-Álvarez R; Sanjurjo-Sáez M
Am J Ther; 2018; 25(3):e393-e394. PubMed ID: 29424756
[No Abstract] [Full Text] [Related]
30. Recurrent CIC Gene Abnormalities in Angiosarcomas: A Molecular Study of 120 Cases With Concurrent Investigation of PLCG1, KDR, MYC, and FLT4 Gene Alterations.
Huang SC; Zhang L; Sung YS; Chen CL; Kao YC; Agaram NP; Singer S; Tap WD; D'Angelo S; Antonescu CR
Am J Surg Pathol; 2016 May; 40(5):645-55. PubMed ID: 26735859
[TBL] [Abstract][Full Text] [Related]
31. Pazopanib, a new therapy for metastatic soft tissue sarcoma.
Verweij J; Sleijfer S
Expert Opin Pharmacother; 2013 May; 14(7):929-35. PubMed ID: 23488774
[TBL] [Abstract][Full Text] [Related]
32. [First Hungarian experience with pazopanib therapy for patients with metastatic renal cancer].
Maráz A; Bodrogi I; Csejtei A; Dank M; Géczi L; Küronya Z; Mangel L; Petrányi A; Szûcs M; Bodoky G
Magy Onkol; 2013 Sep; 57(3):173-6. PubMed ID: 24107823
[TBL] [Abstract][Full Text] [Related]
33. Favorable course of pericardial angiosarcoma under paclitaxel followed by pazopanib treatment documented by cardiovascular magnetic resonance imaging.
Ong P; Greulich S; Schumm J; Backes M; Kaufmann M; Bode-Erdmann S; Ott G; Hebart H; Mahrholdt H
Circulation; 2012 Oct; 126(18):e279-81. PubMed ID: 23109517
[No Abstract] [Full Text] [Related]
34. Treatment patterns and clinical outcomes with pazopanib in patients with advanced soft tissue sarcomas in a compassionate use setting: results of the SPIRE study
Gelderblom H; Judson IR; Benson C; Merimsky O; Grignani G; Katz D; Freivogel KW; Stein D; Jobanputra M; Mungul A; Manson SC; Sanfilippo R
Acta Oncol; 2017 Dec; 56(12):1769-1775. PubMed ID: 28723233
[TBL] [Abstract][Full Text] [Related]
35. Polymorphisms in vascular endothelial growth factor receptor 2 are associated with better response rates to ranibizumab treatment in age-related macular degeneration.
Hermann MM; van Asten F; Muether PS; Smailhodzic D; Lichtner P; Hoyng CB; Kirchhof B; Grefkes C; den Hollander AI; Fauser S
Ophthalmology; 2014 Apr; 121(4):905-10. PubMed ID: 24365177
[TBL] [Abstract][Full Text] [Related]
36. Real-World Clinical Outcomes and Prognostic Factors for Patients with Advanced Angiosarcoma who Received Systemic Treatment.
Park C; Kim M; Kwak Y; Moon KC; Kim SH; Keam B; Kim YJ; Kim TM; Kim DW
Cancer Res Treat; 2021 Oct; 53(4):1195-1203. PubMed ID: 33540493
[TBL] [Abstract][Full Text] [Related]
37. Molecular Signature of Response to Pazopanib Salvage Therapy for Urothelial Carcinoma.
Pinciroli P; Won H; Iyer G; Canevari S; Colecchia M; Giannatempo P; Raggi D; Pierotti MA; De Braud FG; Solit DB; Rosenberg JE; Berger MF; Necchi A
Clin Genitourin Cancer; 2016 Feb; 14(1):e81-90. PubMed ID: 26371421
[No Abstract] [Full Text] [Related]
38. Incorporation of pazopanib in maintenance therapy of ovarian cancer.
du Bois A; Floquet A; Kim JW; Rau J; del Campo JM; Friedlander M; Pignata S; Fujiwara K; Vergote I; Colombo N; Mirza MR; Monk BJ; Kimmig R; Ray-Coquard I; Zang R; Diaz-Padilla I; Baumann KH; Mouret-Reynier MA; Kim JH; Kurzeder C; Lesoin A; Vasey P; Marth C; Canzler U; Scambia G; Shimada M; Calvert P; Pujade-Lauraine E; Kim BG; Herzog TJ; Mitrica I; Schade-Brittinger C; Wang Q; Crescenzo R; Harter P
J Clin Oncol; 2014 Oct; 32(30):3374-82. PubMed ID: 25225436
[TBL] [Abstract][Full Text] [Related]
39. Inhibiting the VEGF-VEGFR pathway in angiosarcoma, epithelioid hemangioendothelioma, and hemangiopericytoma/solitary fibrous tumor.
Park MS; Ravi V; Araujo DM
Curr Opin Oncol; 2010 Jul; 22(4):351-5. PubMed ID: 20485168
[TBL] [Abstract][Full Text] [Related]
40. Second-line pazopanib in patients with relapsed and refractory small-cell lung cancer: a multicentre phase II study of the Hellenic Oncology Research Group.
Koinis F; Agelaki S; Karavassilis V; Kentepozidis N; Samantas E; Peroukidis S; Katsaounis P; Hartabilas E; Varthalitis II; Messaritakis I; Fountzilas G; Georgoulias V; Kotsakis A
Br J Cancer; 2017 Jun; 117(1):8-14. PubMed ID: 28510571
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]